⦿ Executive Snapshot

• What: GH Research PLC reported its financial results for Q1 2026 and provided updates on its clinical trials.
• Who: GH Research PLC, a clinical-stage biopharmaceutical company focused on depression treatment.
• Why it matters: The results and updates signal progress in the development of innovative treatments for treatment-resistant depression (TRD), which could significantly impact patient care and market positioning.

⦿ Key Developments

• Phase 2b results in TRD were published in JAMA Psychiatry, showing remission rates of 53.9%-63.6% across subgroups by Day 8.
• Enrollment for the GH001-HV-106 study was completed, and doses were selected for the global Phase 3 pivotal program for GH001 in TRD.
• Cash and cash equivalents totaled $267.3 million as of March 31, 2026, with an additional $111.2 million raised from an underwritten offering in April 2026.

⦿ Strategic Context

• The company is focused on developing mebufotenin therapies, a novel approach that targets an unmet need in the treatment of TRD, which has seen limited advancement in recent years.
• The publication of Phase 2b trial results in a reputable journal like JAMA Psychiatry enhances credibility and visibility in the competitive biopharmaceutical landscape.

⦿ Strategic Implications

• Immediate implications include increased investor confidence and potential for higher market valuation following successful trial results and funding rounds.
• Long-term implications involve the potential to redefine treatment protocols for TRD and capture significant market share if clinical trials continue to demonstrate efficacy.

⦿ Risks & Constraints

• Potential risks include regulatory challenges with the FDA regarding the pivotal program design and potential clinical holds on future trials.
• Competition from other biopharmaceutical companies developing similar therapies could impact market penetration and financial performance.

⦿ Watchlist / Forward Signals

• The initiation of the global Phase 3 pivotal program for GH001 is targeted for late 2026, which will be a critical milestone.
• Future developments to monitor include FDA feedback on the pivotal program and the outcomes of ongoing and upcoming clinical trials for GH001 and GH002.